We hypothesize that the underlying mechanism by which PPARD variants contribute to individual differences in the development of T2DM and the therapeutic effects of exenatide is that PPARδ regulates the expression and function of GLP-1R. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.